Arsenal Biosciences Closes $220 Million Series B Financing To Advance Programmable Cell Therapy Programs Into Clinical Development
Amount Raised
$220 Million
Round Type
Series B
South San FranciscoBiotechnologyHealth CareTherapeuticsDescription
Arsenal Biosciences, Inc. (ArsenalBio), a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, today announced the close of a $220 million Series B financing round. New investors Softbank Vision Fund 2, Bristol-Myers Squibb Company, Byers Capital, Emerson Collective Investments, Green Sands, Hitachi Ventures, Sixth Street, and others joined existing investors the Parker Institute for Cancer Immunotherapy (PICI), Westlake Village BioPartners, the University of California, San Francisco (UCSF) Foundation Investment Company, Euclidean Capital, Waycross Ventures, and Kleiner Perkins, in supporting the oversubscribed round.
Quick answer
Arsenal Biosciences raised $220 Million in a Series B round, dated September 6, 2022. Arsenal Biosciences is based in South San Francisco, California, United States.
- How much did Arsenal Biosciences raise?
- Arsenal Biosciences raised $220 Million in a Series B round on September 6, 2022.
- What does Arsenal Biosciences do?
- Arsenal Biosciences, Inc. (ArsenalBio), headquartered in South San Francisco, Calif., is a privately held programmable cell therapy company discovering and developing a pipeline of next-generation autologous T cell..
- Where is Arsenal Biosciences based and how big is it?
- Arsenal Biosciences is based in South San Francisco, California, United States.
- Who are the decision-makers at Arsenal Biosciences?
- Fundz holds 1 contact at Arsenal Biosciences, including the Chairman, CEO, Co-Founder. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Arsenal Biosciences that raised within 45 days of this round, from Fundz verified event records.
- Orionis Biosciences raised $55M (Funding Round) on October 19, 2022.
- Insmed Incorporated raised an undisclosed amount (Funding Round) on October 19, 2022.
- SURGE Therapeutics raised $26M (Series A) on October 17, 2022.
- Mablink Bioscience raised $30M (Series A) on October 14, 2022.
- CTRL Therapeutics raised $7.5M on October 12, 2022.
- Neumora raised $112M (Series B) on October 11, 2022.
Who to call at Arsenal Biosciences, and when
A new round usually means Arsenal Biosciences is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Arsenal Biosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Arsenal Biosciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Arsenal Biosciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Arsenal Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansArsenal Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.